Bernard Siegel is the full-time Executive Director of the nonprofit Genetics Policy Institute (GPI) based in Palm Beach Gardens, Florida. He received his undergraduate and law degrees from the University of Miami (BA 1972, JD 1975). He is a member of the Florida Bar since 1975.
In 2002, Mr. Siegel filed the landmark case seeking a guardian for the alleged clone, "Baby Eve." The case was widely credited for exposing Clonaid , the so-called "human cloning company" as a sham. In 2003, he traded his 30-year courtroom career to found GPI, which leads the global cause in support of stem cell research. He is a recognized policy expert relating to stem cell research, regenerative medicine and cloning. Working with the world's leading stem cell researchers,
Mr. Siegel played a pivotal role in protecting the research in the United Nations, which was under the threat of being banned by world treaty. He also works with grassroots activists throughout the United States, educating lawmakers and formulating effective strategies supporting research for cures.
Mr. Siegel serves on the board of directors of Americans for Cures and on the advisory boards of the Sabrina Cohen Foundation for Stem Cell Research, The Brooke Ellison Project and Genomics Education Institute. He is a member of the American Society for Bioethics + Humanities. He is a member of the International Society for Stem Cell Research and serves as the co-chair of the ISSCR Governmental Affairs Committee.
Mr. Siegel has been recognized for his achievements. His honors include the 2005 Advocacy Award from the Stem Cell Action Network. In May 2006, he was voted one of the "dLife Top 10" individuals who made the greatest contribution to the lives of people with diabetes in 2005.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?